By Suzy Cohen
Dear Pharmacist,
I bought your Drug Muggers book and learned that coffee is stealing iron from my body. I’ve had chronic fatigue for years, and now that I’m supplementing with the iron, I’m feeling MUCH better, so thank you! I’m not giving up coffee though. Suzy, would you be willing to share more drug muggers, as a public service, because some people can’t afford to buy your book, but they really need your help. --K.M., Kansas City, Kansas
Answer: Yes, of course and I’ve been sharing this information freely since 1999. The drug mugging effect can explain everything from nagging aches to life-threatening diseases. Replenishing the missing nutrient(s) might be just what the doctor should have ordered! Most people don’t know this but years ago, I asked major publishers to make a book out of this information, but none understood the importance of it, and some felt it would step on pharmaceutical toes. So I spent my own savings to publish “Drug Muggers” and now that book is sold at Amazon.com, NaturalNews.com and my own website, www.DearPharmacist.com where I offer free articles on the topic. For now, here are some very common ‘diseases’ that might be due to to the drug mugging effect:
Depression, osteoporosis or irregular heartbeat- It could be caused by a deficiency of the mineral magnesium. Common drug muggers include female hormones, diuretics, raloxifene, tea/coffee, anti-inflammatories and aspirin.
Bald patches, loss of taste/smell, erectile dysfunction or chronic diarrhea- It might be zinc deficiency. Common drug muggers are anti-inflammatories, antibiotics, antacids, ulcer/heartburn meds, diuretics and estrogen drugs used for birth control and menopause.
Leg cramps, muscle spasms, memory loss or fatigue- May be a deficiency of CoQ10 (ubiquinol). This life-sustaining antioxidant gets demolished by hundreds of medications including statin cholesterol drugs, metformin, anti-depressants, beta blockers and diuretics. I’ve posted a “Big List of Drugs that Mug CoQ10” for free at my website.
Cell damage, high homocysteine, cataracts, macular degeneration, liver problems- It could be tied to low glutathione, a powerful antioxidant needed to detoxify poisons in your body. Acetaminophen is a possible drug mugger of glutathione.
Pins and needles nerve pain, depression, fatigue, anemia, weight gain- This could be related to a deficiency of B vitamins. Your stash gets depleted by female hormones (menopause and birth control), antacids, ulcer meds, diuretics, raloxifene, cholestyramine, diabetic drugs, tea/coffee.
If you read this and just said, “Aha!” then get approval from your doctor to supplement, or order “micronutrient” testing. For pennies a day, you can get your life back! If you decide to wait and see if I’m right (and not replenish what the drug mugger is stealing), then expect these so-called side effects to get diagnosed as a new disease. You’ll get on a medication merry-go-round and it’s a hard ride to get off.
Wednesday, June 2, 2010
Thursday, May 27, 2010
Smoking Increases The Risk Of Age Related Macular Degeneration
American Chronicle - Hayden Eck
Age related macular degeneration (AMD) is characterized by problems in the sharp and central vision of a person. It usually affects people who are 60 years and older and is one of the leading causes of vision loss.
Smoking and AMD
Various studies have provided conclusive results that link smoking with an increased risk of suffering from AMD. The chance of suffering from AMD both, atrophic age related macular degeneration and neo-vascular degeneration double in smokers. The studies have also shown that former smokers don´t show the same risk of suffering from this condition; and if compared to people who never smoked, the dice is just about loaded in favour of non smokers. Another finding of the study was that as a smoker you can develop AMD around ten years before non smokers. These studies also draw a link between specific genetic background, heavy smoking, and the risk of AMD. It´s been seen that there is a dramatic increase in the risk factor.
Quit smoking to reduce risk
AMD causes blindness. No two ways about the fact. If you don´t want to lose your vision, it´s important that you do something about your smoking habit. So, what is it that you want to do? Cutting down on your smoking habit is not going to help matters much. You need to cut down completely on cigarettes. It´s not going to be an easy task but you need to quit smoking. If you are having trouble quitting, you can take the help of prescription quit smoking pills like Chantix to help in your efforts to quit smoking.
Accurate and timely diagnosis of AMD
If you think you are facing chronic problems with your vision, its time that you consult your doctor. More so, if you are a smoker! A regular checkup session with your doctor is necessary to know if you are suffering from this condition. AMD is a progressive condition, so you don´t really want to leave it till very late to start off on a treatment plan. Any doctor will tell you that the first thing you must do to help manage your condition is to quit smoking. The doctor can also recommend the intake of various medications along with your quit smoking endeavor. If you have already begun your intake of prescription medications like Chantix, it´s important to make sure that you aren´t going to suffer from any adverse interaction of taking these medications.
Not just another risk factor of smoking
Many smokers might regard AMD as just another health risk of smoking. Also, the fact that it usually manifests itself when you are older, might also contribute to you not giving the due importance to this condition. But, the fact of the matter is that it needs to be treated with due seriousness, because if you don´t, you might start losing your vision. This is going to have a huge impact on the general quality of life. So, why wait for that to happen before you realize the seriousness of the situation.
Hayden Eck - Webmaster of leading online health clinic Chantix-Buy.com, has been providing health newsletters and articles since last three years. He discusses smoking effects with brief description about quit smoking pills
Age related macular degeneration (AMD) is characterized by problems in the sharp and central vision of a person. It usually affects people who are 60 years and older and is one of the leading causes of vision loss.
Smoking and AMD
Various studies have provided conclusive results that link smoking with an increased risk of suffering from AMD. The chance of suffering from AMD both, atrophic age related macular degeneration and neo-vascular degeneration double in smokers. The studies have also shown that former smokers don´t show the same risk of suffering from this condition; and if compared to people who never smoked, the dice is just about loaded in favour of non smokers. Another finding of the study was that as a smoker you can develop AMD around ten years before non smokers. These studies also draw a link between specific genetic background, heavy smoking, and the risk of AMD. It´s been seen that there is a dramatic increase in the risk factor.
Quit smoking to reduce risk
AMD causes blindness. No two ways about the fact. If you don´t want to lose your vision, it´s important that you do something about your smoking habit. So, what is it that you want to do? Cutting down on your smoking habit is not going to help matters much. You need to cut down completely on cigarettes. It´s not going to be an easy task but you need to quit smoking. If you are having trouble quitting, you can take the help of prescription quit smoking pills like Chantix to help in your efforts to quit smoking.
Accurate and timely diagnosis of AMD
If you think you are facing chronic problems with your vision, its time that you consult your doctor. More so, if you are a smoker! A regular checkup session with your doctor is necessary to know if you are suffering from this condition. AMD is a progressive condition, so you don´t really want to leave it till very late to start off on a treatment plan. Any doctor will tell you that the first thing you must do to help manage your condition is to quit smoking. The doctor can also recommend the intake of various medications along with your quit smoking endeavor. If you have already begun your intake of prescription medications like Chantix, it´s important to make sure that you aren´t going to suffer from any adverse interaction of taking these medications.
Not just another risk factor of smoking
Many smokers might regard AMD as just another health risk of smoking. Also, the fact that it usually manifests itself when you are older, might also contribute to you not giving the due importance to this condition. But, the fact of the matter is that it needs to be treated with due seriousness, because if you don´t, you might start losing your vision. This is going to have a huge impact on the general quality of life. So, why wait for that to happen before you realize the seriousness of the situation.
Hayden Eck - Webmaster of leading online health clinic Chantix-Buy.com, has been providing health newsletters and articles since last three years. He discusses smoking effects with brief description about quit smoking pills
Friday, January 22, 2010
Acucela Enters Fast-Growth Phase As Macular Degeneration Drug Advances to Key Trial
Acucela has the ambitious goal of fundamentally changing the way doctors treat the so-called “dry” form of age-related macular degeneration, which damages the eyesight of an estimated 29 million elderly people worldwide. The company was spun out of the University of Washington in 2002 by Ryo Kubota, an ophthalmologist on the faculty at the time. His dream is to create a once-daily oral pill that can slow down the progressive vision loss that comes with the dry form of macular degeneration, and ultimately to keep these aging patients from going blind.
The company got a big lift in September 2008 when it struck a partnership with Japan-based Otsuka Pharmaceutical to co-develop its lead drug candidate, and this month it took another big step by entering the first clinical trial that will assess what kind of effect its drug will have on the eyesight of between 50 to 100 elderly patients.
“We want to build a great company, and we want to build it to last. Our investors and our partner believes in it,” Kubota says.
Since Acucela doesn’t usually make a lot of news, some background is certainly in order. Acucela is vying to develop the first effective therapy for the dry form of age-related macular degeneration. It’s caused by yellowish buildups and a loss of pigment in the retina as people age. There is no approved treatment for this disease, unlike the “wet” form of age-related macular degeneration, which can be treated with Roche’s bevacizumab (Avastin) and ranibizumab (Lucentis), which cut off blood flow to leaky vessels behind the eye. The dry form of the disease is generally milder, but the market opportunity is thought to be huge, because as populations around the world age, it is expected to double in incidence over the next two decades.
Acucela’s idea comes in the form of a once-daily pill it calls ACU-4429. The drug is designed to block an enzyme called isomerase. By blocking that enzyme, Acucela hopes to slow down the visual cycle in which Vitamin A is constantly replenished. While people need a constant source of Vitamin A to see, a fast visual cycle can also contribute to the buildup of toxic Vitamin A byproducts in the eye, particularly one called A2E.
Back in May, Acucela presented the first evidence from a clinical trial that said its drug was on track. The initial trial enrolled 36 healthy volunteers at an escalating series of doses, and basically concluded that the drug was safe and well-tolerated.
This month, Acucela is attempting to pass a tougher test. The company started enrolling elderly people with severe cases of the dry form of macular degeneration. The trial, called Envision, will randomly assign patients to get the drug, or a placebo, at a variety of once-daily doses. Patients will be followed up for three months, and researchers will look at how well they can read letters on the eye chart, and a secondary goal that will assess whether the drug is working as intended, by reducing the amount of toxic byproduct buildup in the eye. It’s possible that the trial, as long as it appears safe at escalating doses, could enroll as many as 100 patients, Kubota says. It’s expected to take about one year to complete enrollment, and results should be available by mid-2011, he says.
Although Acucela is entering uncharted territory with a new way of treating this disease, it has competition from Tampa, FL-based Sirion Therapeutics. The competing drug is an oral pill like Acucela’s, made to circulate through the bloodstream, although it is designed to hit a different target than Acucela’s, Kubota says.
While Acucela awaits results from its mid-stage clinical trial, it is working to build up a lot of organizational strength this year, Kubota says. People with expertise in clinical development, preclinical development, and regulatory affairs are being recruited this year. By the end of 2010, Acucela expects to have hired about 60 new people, bringing its staff to about 100, he says. The company hopes to have that organizational horsepower in place by the time it expects to enter the final phase of clinical trials with ACU-4429, for an even more rigorous study that will assess patients’ vision for 18 to 24 months, Kubota says.
Although it’s rare among biotech companies without marketed products, Acucela has been able to operate on a cash-flow positive basis of late, Kubota says. That’s because Otsuka is paying for the company’s R&D expenses, while Acucela has received undisclosed milestone payments for getting this far in development, Kubota says.
“We’re going to be running big clinical trials,” Kubota says. “We think we can change the disease paradigm. Our goal is to cure blindness. It’s a huge ambition.”
For more information go to www.maculardegenerationassociation.org
The company got a big lift in September 2008 when it struck a partnership with Japan-based Otsuka Pharmaceutical to co-develop its lead drug candidate, and this month it took another big step by entering the first clinical trial that will assess what kind of effect its drug will have on the eyesight of between 50 to 100 elderly patients.
“We want to build a great company, and we want to build it to last. Our investors and our partner believes in it,” Kubota says.
Since Acucela doesn’t usually make a lot of news, some background is certainly in order. Acucela is vying to develop the first effective therapy for the dry form of age-related macular degeneration. It’s caused by yellowish buildups and a loss of pigment in the retina as people age. There is no approved treatment for this disease, unlike the “wet” form of age-related macular degeneration, which can be treated with Roche’s bevacizumab (Avastin) and ranibizumab (Lucentis), which cut off blood flow to leaky vessels behind the eye. The dry form of the disease is generally milder, but the market opportunity is thought to be huge, because as populations around the world age, it is expected to double in incidence over the next two decades.
Acucela’s idea comes in the form of a once-daily pill it calls ACU-4429. The drug is designed to block an enzyme called isomerase. By blocking that enzyme, Acucela hopes to slow down the visual cycle in which Vitamin A is constantly replenished. While people need a constant source of Vitamin A to see, a fast visual cycle can also contribute to the buildup of toxic Vitamin A byproducts in the eye, particularly one called A2E.
Back in May, Acucela presented the first evidence from a clinical trial that said its drug was on track. The initial trial enrolled 36 healthy volunteers at an escalating series of doses, and basically concluded that the drug was safe and well-tolerated.
This month, Acucela is attempting to pass a tougher test. The company started enrolling elderly people with severe cases of the dry form of macular degeneration. The trial, called Envision, will randomly assign patients to get the drug, or a placebo, at a variety of once-daily doses. Patients will be followed up for three months, and researchers will look at how well they can read letters on the eye chart, and a secondary goal that will assess whether the drug is working as intended, by reducing the amount of toxic byproduct buildup in the eye. It’s possible that the trial, as long as it appears safe at escalating doses, could enroll as many as 100 patients, Kubota says. It’s expected to take about one year to complete enrollment, and results should be available by mid-2011, he says.
Although Acucela is entering uncharted territory with a new way of treating this disease, it has competition from Tampa, FL-based Sirion Therapeutics. The competing drug is an oral pill like Acucela’s, made to circulate through the bloodstream, although it is designed to hit a different target than Acucela’s, Kubota says.
While Acucela awaits results from its mid-stage clinical trial, it is working to build up a lot of organizational strength this year, Kubota says. People with expertise in clinical development, preclinical development, and regulatory affairs are being recruited this year. By the end of 2010, Acucela expects to have hired about 60 new people, bringing its staff to about 100, he says. The company hopes to have that organizational horsepower in place by the time it expects to enter the final phase of clinical trials with ACU-4429, for an even more rigorous study that will assess patients’ vision for 18 to 24 months, Kubota says.
Although it’s rare among biotech companies without marketed products, Acucela has been able to operate on a cash-flow positive basis of late, Kubota says. That’s because Otsuka is paying for the company’s R&D expenses, while Acucela has received undisclosed milestone payments for getting this far in development, Kubota says.
“We’re going to be running big clinical trials,” Kubota says. “We think we can change the disease paradigm. Our goal is to cure blindness. It’s a huge ambition.”
For more information go to www.maculardegenerationassociation.org
Sunday, January 10, 2010
Injections, supplements can help limit age-related macular degeneration
Three years ago, Catherine Leisher began noticing words were blurred when she read the newspaper. A trip to the eye doctor yielded diagnosis of a condition she had never heard of: age-related macular degeneration.
“I can see to walk, I can look out the window, and I can write,” said the 83-year-old Swatara Twp. resident who has the disease in both eyes. “But I can’t read — it’s all blurred, and I just loved to read.”
Age-related macular degeneration, which affects some 15 million Americans, leads to damage of the macula, which is the central part of the retina responsible for central vision and controls the ability to read, drive and recognize people’s faces in detail.
“It’s a major public health issue,” said Dr. Ingrid Scott, professor of ophthalmology and public health sciences at Penn State Milton S. Hershey Medical Center. “Age-related macular degeneration is the leading cause of vision impairment and blindness in people over the age of 50 in the United States and the industrialized world.”
The incidence is expected to increase as baby boomers age, said Dr. Erik Chotiner, an ophthalmologist with Memorial Eye Institute in Lower Paxton Twp. “Statistics say that 1.75 million people have advanced AMD now, but that number is expected to rise to 2.95 million by 2025,” he said.
There are two types of the disease, dry and wet, which both can distort vision. Dry macular degeneration, the most common form, usually progresses gradually. The wet form, which occurs when abnormal or leaking blood vessels grow underneath the retina in the area of the macula, can lead to more rapid loss of central vision.
At first, Leisher, who suffers from the wet form, was frightened that she would eventually become blind. However, new drugs injected directly into the eye offer hope to people who suffer from the wet form of AMD.
The drugs, available since 2004, are called anti-VEGF, which stands for “vascular endothelial growth factor” — a family of proteins shown to be important in causing the growth of abnormal blood vessels that characterizes wet macular degeneration.
“Before these drugs, treatment was more primitive and really only helped stabilize, not improve, vision,” Chotiner said.
The anti-VEGF medications, which are injected into the back of the eye with a small needle, work by decreasing the growth of abnormal, leaky blood vessels.
“It can be uncomfortable, but I’ve never had a patient who wasn’t able to tolerate it,” said Scott, who administers a numbing medication to the eye before giving the shot. “With anti-VEGF drugs, 40 percent of patients have visual improvement, and 95 percent have stabilization of vision.”
“My vision is brighter,” said Leisher, who receives her injections at Penn State Milton S. Hershey Medical Center. “A lot of people I know won’t take the shots because they are afraid of the needle. I hesitated at first, but I think I’d be much worse off if I didn’t do it.”
Another option, called photodynamic therapy, involves injecting a photosensitive drug into a vein in the arm. The dye travels to the blood vessels in the eye and localizes preferentially to the abnormal blood vessels. A cold laser beam is shown into the eye and temporarily reduces blood flow to the abnormal blood vessels. This therapy can slow the rate of vision loss but is much less likely to improve vision like the anti-VEGF medications can, Scott said.
Randee Erb, a 62-year-old New Holland resident diagnosed with wet macular degeneration last spring, has had four anti-VEGF injections and is noticing that her blurred vision is better.
“I dread getting the shots,” said Erb, who has to take the day off work when she gets the injections because they make her eye burn. “But they give me hope that I will be able to see clearly again.”
Every day Erb tests her eyesight by looking at an Amsler grid, a chart of vertical and horizontal lines, which she has taped to her refrigerator. The grid helps patients gauge whether their vision is worsening and they should see their doctor, based on how clear and straight the lines appear. As in Erb’s case the daily exercise can also bring good news. “At first it was all gray; now I’m slowly seeing lines,” she said.
Some patients with AMD might benefit from taking vitamin supplements that can reduce the risk of severe vision loss due to the disease by 25 percent and/or reduce the risk of developing wet AMD by 25 percent, Scott said. Called the AREDS formulation, it includes vitamins A, C, E, zinc and copper.
There are preventative measures that people can take to decrease their chances of developing AMD, doctors said. These include wearing sunglasses, not smoking, cutting down on saturated fats and eating dark green, leafy and orange vegetables such as broccoli, spinach, carrots and sweet potatoes.
“It’s extremely important to have regular eye exams,” Scott said. “People have often just accepted a decline in vision as part of aging when, in fact, many causes of declining vision can be treated. For example, it’s been shown in clinical trial after clinical trial among patients with wet AMD that the leading predictive factor for a patient’s visual outcome is how early they are diagnosed and treated.”
For more information go to WWW.MACULARDEGENERATIONASSOCIATION.ORG
“I can see to walk, I can look out the window, and I can write,” said the 83-year-old Swatara Twp. resident who has the disease in both eyes. “But I can’t read — it’s all blurred, and I just loved to read.”
Age-related macular degeneration, which affects some 15 million Americans, leads to damage of the macula, which is the central part of the retina responsible for central vision and controls the ability to read, drive and recognize people’s faces in detail.
“It’s a major public health issue,” said Dr. Ingrid Scott, professor of ophthalmology and public health sciences at Penn State Milton S. Hershey Medical Center. “Age-related macular degeneration is the leading cause of vision impairment and blindness in people over the age of 50 in the United States and the industrialized world.”
The incidence is expected to increase as baby boomers age, said Dr. Erik Chotiner, an ophthalmologist with Memorial Eye Institute in Lower Paxton Twp. “Statistics say that 1.75 million people have advanced AMD now, but that number is expected to rise to 2.95 million by 2025,” he said.
There are two types of the disease, dry and wet, which both can distort vision. Dry macular degeneration, the most common form, usually progresses gradually. The wet form, which occurs when abnormal or leaking blood vessels grow underneath the retina in the area of the macula, can lead to more rapid loss of central vision.
At first, Leisher, who suffers from the wet form, was frightened that she would eventually become blind. However, new drugs injected directly into the eye offer hope to people who suffer from the wet form of AMD.
The drugs, available since 2004, are called anti-VEGF, which stands for “vascular endothelial growth factor” — a family of proteins shown to be important in causing the growth of abnormal blood vessels that characterizes wet macular degeneration.
“Before these drugs, treatment was more primitive and really only helped stabilize, not improve, vision,” Chotiner said.
The anti-VEGF medications, which are injected into the back of the eye with a small needle, work by decreasing the growth of abnormal, leaky blood vessels.
“It can be uncomfortable, but I’ve never had a patient who wasn’t able to tolerate it,” said Scott, who administers a numbing medication to the eye before giving the shot. “With anti-VEGF drugs, 40 percent of patients have visual improvement, and 95 percent have stabilization of vision.”
“My vision is brighter,” said Leisher, who receives her injections at Penn State Milton S. Hershey Medical Center. “A lot of people I know won’t take the shots because they are afraid of the needle. I hesitated at first, but I think I’d be much worse off if I didn’t do it.”
Another option, called photodynamic therapy, involves injecting a photosensitive drug into a vein in the arm. The dye travels to the blood vessels in the eye and localizes preferentially to the abnormal blood vessels. A cold laser beam is shown into the eye and temporarily reduces blood flow to the abnormal blood vessels. This therapy can slow the rate of vision loss but is much less likely to improve vision like the anti-VEGF medications can, Scott said.
Randee Erb, a 62-year-old New Holland resident diagnosed with wet macular degeneration last spring, has had four anti-VEGF injections and is noticing that her blurred vision is better.
“I dread getting the shots,” said Erb, who has to take the day off work when she gets the injections because they make her eye burn. “But they give me hope that I will be able to see clearly again.”
Every day Erb tests her eyesight by looking at an Amsler grid, a chart of vertical and horizontal lines, which she has taped to her refrigerator. The grid helps patients gauge whether their vision is worsening and they should see their doctor, based on how clear and straight the lines appear. As in Erb’s case the daily exercise can also bring good news. “At first it was all gray; now I’m slowly seeing lines,” she said.
Some patients with AMD might benefit from taking vitamin supplements that can reduce the risk of severe vision loss due to the disease by 25 percent and/or reduce the risk of developing wet AMD by 25 percent, Scott said. Called the AREDS formulation, it includes vitamins A, C, E, zinc and copper.
There are preventative measures that people can take to decrease their chances of developing AMD, doctors said. These include wearing sunglasses, not smoking, cutting down on saturated fats and eating dark green, leafy and orange vegetables such as broccoli, spinach, carrots and sweet potatoes.
“It’s extremely important to have regular eye exams,” Scott said. “People have often just accepted a decline in vision as part of aging when, in fact, many causes of declining vision can be treated. For example, it’s been shown in clinical trial after clinical trial among patients with wet AMD that the leading predictive factor for a patient’s visual outcome is how early they are diagnosed and treated.”
For more information go to WWW.MACULARDEGENERATIONASSOCIATION.ORG
Monday, January 4, 2010
Smoking Increases Risk Of Age-Related Macular Degeneration
According to a new study, it is not a good idea for older people to continue to smoke, as smoking is the second most common risk factor for developing age-related macular degeneration (AMD).
AMD is a disease that progressively damages the macula i. e. the centre of the retina that makes it possible for us see fine details. Degeneration of the macula prevents people from being able to read, recognise faces or drive, due to experiencing darkness or blurring of their central vision.
What this means is that it is never too late to quit smoking, as even the eyes of the elderly benefit from kicking the habit.
The new study trying to determine whether age influences the effects of smoking on the risk of developing AMD, followed a group of 1,958-women of whom 75 smoked. These women 78-years of age at the start of the baseline exam underwent retinal photographs at five year intervals.
Their retinal images were compared at ages 78 and 83 to see whether AMD had made an appearance, including evaluating whether smoking played a role in their likelihood of developing the disease.
Researchers found that the women who smoked had 11% higher rates of AMD overall, than other women of the same age. As well, they found that 80-plus women who smoked were 5.5-times more likely than the same age women who did not smoke to develop AMD.
The bottom line is that aging increases the risk of AMD, but smoking raises the risk even more.
The study’s findings have been published in the January edition of the American Journal of Ophthalmology.
For more information go to www.maculardegenerationassociation.org
AMD is a disease that progressively damages the macula i. e. the centre of the retina that makes it possible for us see fine details. Degeneration of the macula prevents people from being able to read, recognise faces or drive, due to experiencing darkness or blurring of their central vision.
What this means is that it is never too late to quit smoking, as even the eyes of the elderly benefit from kicking the habit.
The new study trying to determine whether age influences the effects of smoking on the risk of developing AMD, followed a group of 1,958-women of whom 75 smoked. These women 78-years of age at the start of the baseline exam underwent retinal photographs at five year intervals.
Their retinal images were compared at ages 78 and 83 to see whether AMD had made an appearance, including evaluating whether smoking played a role in their likelihood of developing the disease.
Researchers found that the women who smoked had 11% higher rates of AMD overall, than other women of the same age. As well, they found that 80-plus women who smoked were 5.5-times more likely than the same age women who did not smoke to develop AMD.
The bottom line is that aging increases the risk of AMD, but smoking raises the risk even more.
The study’s findings have been published in the January edition of the American Journal of Ophthalmology.
For more information go to www.maculardegenerationassociation.org
Monday, December 14, 2009
New Macula Eye Disease Discovered
University of Lowa’s scientists have come out with a finding about a new inherited eye disease that affects a part of the retina called the macula. Macula is the part of retina that forms the high-resolution central vision area.
Macula gets damaged in retinal conditions like macular degeneration and can even suffer in case if the person is a patient of diabetes. Macula plays an integral role especially while reading and driving. The new inherited disease came into the attention of the scientists after a person from United States approached a doctor for eye problem. The finding of the disease is expected to increase the comprehension of other common retinal diseases.
Study's lead author Vinit Mahajan, MD, Ph.D., assistant professor of ophthalmology and visual sciences at the University of Iowa Roy J and Lucille A Carver College of Medicine said, "It is rare to find a new inherited eye disease that affects the macula. We thought we had seen them all." He added, "This newly found retinal disease causes abnormal blood vessels in the macula, and these vessels are prone to bleeding. This causes swelling or scars that ''black out'' or blur parts of the field of vision."
"If a doctor saw just one family member, they would probably call this macular degeneration. We knew there was something different, and we had to examine the rest of the family," Mahajan said.
The whole team of scientists evaluated 20 extended family members who had some or other problem with their eyes. Some were reported with central vision loss while others suffered from strabismus which is a condition of where eyes are not aligned. The findings have been reported in the November 9 issue of the Archives of ophthalmology.
For more information go to www.maculardegenerationassociation.org
Macula gets damaged in retinal conditions like macular degeneration and can even suffer in case if the person is a patient of diabetes. Macula plays an integral role especially while reading and driving. The new inherited disease came into the attention of the scientists after a person from United States approached a doctor for eye problem. The finding of the disease is expected to increase the comprehension of other common retinal diseases.
Study's lead author Vinit Mahajan, MD, Ph.D., assistant professor of ophthalmology and visual sciences at the University of Iowa Roy J and Lucille A Carver College of Medicine said, "It is rare to find a new inherited eye disease that affects the macula. We thought we had seen them all." He added, "This newly found retinal disease causes abnormal blood vessels in the macula, and these vessels are prone to bleeding. This causes swelling or scars that ''black out'' or blur parts of the field of vision."
"If a doctor saw just one family member, they would probably call this macular degeneration. We knew there was something different, and we had to examine the rest of the family," Mahajan said.
The whole team of scientists evaluated 20 extended family members who had some or other problem with their eyes. Some were reported with central vision loss while others suffered from strabismus which is a condition of where eyes are not aligned. The findings have been reported in the November 9 issue of the Archives of ophthalmology.
For more information go to www.maculardegenerationassociation.org
Thursday, December 3, 2009
First New Embryonic Stem Cell Lines Approved for U.S.
Thirteen embryonic stem-cell lines were approved for use by U.S.-funded researchers today, the first of hundreds of cell colonies that may become available under new polices promised by President Barack Obama.
Stem cells taken from days-old human embryos can be kept alive indefinitely in solution, and have the ability to turn into about 200 cell types in the body. Use of these so-called cell lines is opposed by some people because extracting them destroys the embryos. The stem-cell expansion was announced today by Francis Collins, director of the National Institutes of Health, in a telephone briefing with reporters.
Another 20 lines may be cleared as soon as Dec. 4, the first of “a wave” of approvals that could make hundreds available, Collins said. Obama pledged to end U.S. stem-cell restrictions during his presidential campaign. Congress twice voted to overturn the limits, put in place by President George W. Bush, and Bush vetoed both measures.
“With these restrictions now being lifted, we can now compete, hopefully, with the U.K. and some of the other foreign governments that are running with us,” said Robert Lanza, chief scientific officer of Worcester, Massachusetts-based Advanced Cell Technology Inc., in a telephone interview today. “It would be good for us to be back in the game.”
Advanced Cell gained 1 cent to reach 11 cents in over-the- counter trading at 4 p.m. New York time. The shares more than tripled this year. Geron, the Menlo Park, California company whose application to start the first human trial using embryonic stem cells is pending before the U.S. Food and Drug Administration, rose 76 cents, or 14 percent, to $6.20 in Nasdaq Stock Market trading. The increase was the biggest single-day gain for the company in more than four months.
10,000 Shares
Redwood Partners, a New York-based investment firm, bought 10,000 shares of Geron at $5.70 off the news, said Lisa Duffee, a trader with the company, in a telephone interview today.
“These sorts of stocks get crazy when there’s news,” she said. “They react strongly to the upside or the downside and they’re not expensive. We may hold on to them for a few days to see how much noise it gets. If it really runs up, we could be out today.”
The newly approved lines were created by George Daley, a researcher at Harvard University in Cambridge, Massachusetts and Ali Brivanlou, a researcher at Rockefeller University in New York. They were made using private donations during the eight years that federal funding for stem-cell research was sharply restricted by the Bush administration.
‘Huge Relief’
“It’s been a long time coming and it’s a huge relief,” said Daley, whose research team at the Harvard Stem Cell Institute created 11 of the newly approved lines. “This is the first step toward widely expanded access to hundreds of lines that have been derived since the initial Bush policy of 2001.”
Collins said his agency has approved 31 grants totaling $21 million that have been held up until new cell lines were reviewed and approved. The scientists awarded the grants can now choose which approved cell lines to work with, he said.
“This is an opportunity to celebrate the science that can now go forward,” Collins said during the briefing. The announcement should end “what has clearly been a time of some frustration on the part of the research community.”
More embryonic stem-cell grant applications are under review by the NIH as part of the $10 billion provided to the agency in the $787 stimulus package passed by Congress in February, Collins said. Those grants are in the second stage of scrutiny at the agency and may lead to more than $10 million in additional awards, he said.
‘Rigorous’ Review
The NIH conducted a “rigorous” review to make sure the stem cells approved today were made from embryos that were freely donated by women who were not compensated or induced in any way to provide them, Collins said. Scientists had to submit evidence that donors were informed of all options on use of their embryos and provided written consent.
David Prentice, a senior fellow for life sciences at the Family Research Council in Washington, described the new approvals as “unfortunate,” saying stem-cell research had yet to produce results.
“This money would be much better spent on adult stem cell research where we are seeing good results for a variety of diseases including stroke, spinal cord injury and multiple sclerosis,” he said.
Eye Diseases
Advanced Cell Technology applied to U.S. regulators last month to start human trials on its embryonic stem-cell treatment for Stargardt’s Macular Dystrophy, which causes untreatable blindness. The treatment resulted in 100 percent restoration of vision in rat studies with no serious side effects, Lanza said.
The stem-cell colony used in the studies, which wasn’t previously approved for federal research funding, is five to ten times as efficient at replacing lost photoreceptor cells as other lines, Lanza said.
The company plans to pursue the treatment for other forms of macular degeneration, which affects as many as 10 million people in the U.S., according to a company statement.
For more information go to www.maculardegenerationassociation.org
Stem cells taken from days-old human embryos can be kept alive indefinitely in solution, and have the ability to turn into about 200 cell types in the body. Use of these so-called cell lines is opposed by some people because extracting them destroys the embryos. The stem-cell expansion was announced today by Francis Collins, director of the National Institutes of Health, in a telephone briefing with reporters.
Another 20 lines may be cleared as soon as Dec. 4, the first of “a wave” of approvals that could make hundreds available, Collins said. Obama pledged to end U.S. stem-cell restrictions during his presidential campaign. Congress twice voted to overturn the limits, put in place by President George W. Bush, and Bush vetoed both measures.
“With these restrictions now being lifted, we can now compete, hopefully, with the U.K. and some of the other foreign governments that are running with us,” said Robert Lanza, chief scientific officer of Worcester, Massachusetts-based Advanced Cell Technology Inc., in a telephone interview today. “It would be good for us to be back in the game.”
Advanced Cell gained 1 cent to reach 11 cents in over-the- counter trading at 4 p.m. New York time. The shares more than tripled this year. Geron, the Menlo Park, California company whose application to start the first human trial using embryonic stem cells is pending before the U.S. Food and Drug Administration, rose 76 cents, or 14 percent, to $6.20 in Nasdaq Stock Market trading. The increase was the biggest single-day gain for the company in more than four months.
10,000 Shares
Redwood Partners, a New York-based investment firm, bought 10,000 shares of Geron at $5.70 off the news, said Lisa Duffee, a trader with the company, in a telephone interview today.
“These sorts of stocks get crazy when there’s news,” she said. “They react strongly to the upside or the downside and they’re not expensive. We may hold on to them for a few days to see how much noise it gets. If it really runs up, we could be out today.”
The newly approved lines were created by George Daley, a researcher at Harvard University in Cambridge, Massachusetts and Ali Brivanlou, a researcher at Rockefeller University in New York. They were made using private donations during the eight years that federal funding for stem-cell research was sharply restricted by the Bush administration.
‘Huge Relief’
“It’s been a long time coming and it’s a huge relief,” said Daley, whose research team at the Harvard Stem Cell Institute created 11 of the newly approved lines. “This is the first step toward widely expanded access to hundreds of lines that have been derived since the initial Bush policy of 2001.”
Collins said his agency has approved 31 grants totaling $21 million that have been held up until new cell lines were reviewed and approved. The scientists awarded the grants can now choose which approved cell lines to work with, he said.
“This is an opportunity to celebrate the science that can now go forward,” Collins said during the briefing. The announcement should end “what has clearly been a time of some frustration on the part of the research community.”
More embryonic stem-cell grant applications are under review by the NIH as part of the $10 billion provided to the agency in the $787 stimulus package passed by Congress in February, Collins said. Those grants are in the second stage of scrutiny at the agency and may lead to more than $10 million in additional awards, he said.
‘Rigorous’ Review
The NIH conducted a “rigorous” review to make sure the stem cells approved today were made from embryos that were freely donated by women who were not compensated or induced in any way to provide them, Collins said. Scientists had to submit evidence that donors were informed of all options on use of their embryos and provided written consent.
David Prentice, a senior fellow for life sciences at the Family Research Council in Washington, described the new approvals as “unfortunate,” saying stem-cell research had yet to produce results.
“This money would be much better spent on adult stem cell research where we are seeing good results for a variety of diseases including stroke, spinal cord injury and multiple sclerosis,” he said.
Eye Diseases
Advanced Cell Technology applied to U.S. regulators last month to start human trials on its embryonic stem-cell treatment for Stargardt’s Macular Dystrophy, which causes untreatable blindness. The treatment resulted in 100 percent restoration of vision in rat studies with no serious side effects, Lanza said.
The stem-cell colony used in the studies, which wasn’t previously approved for federal research funding, is five to ten times as efficient at replacing lost photoreceptor cells as other lines, Lanza said.
The company plans to pursue the treatment for other forms of macular degeneration, which affects as many as 10 million people in the U.S., according to a company statement.
For more information go to www.maculardegenerationassociation.org
Subscribe to:
Posts (Atom)
